andexanet
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Andexanet alfa is the newly approved factor Xa inhibitor reversal agent for the treatment of life-threatening or uncontrolled…
The direct oral anticoagulants (DOACs) have gained popularity recently among both patients and providers for their comparable or…
Research idea and study design: MEG, RPN; data analysis/interpretation: AS; synthesis and manuscript drafting: RS, AS, MEG, RPN…
Oral fostamatinib is an orally administered small molecule spleen tyrosine kinase (SYK) inhibitor approved for the treatment of…
Recently, a study about andexanet for reversal of bleeding associated with factor Xa inhibitors has been published [1]. In this…
Important market catalysts expected in the third quarter of 2016 include an FDA approval decision for the universal factor Xa…
Bleeding is a potential complication with factor Xa inhibitors, but two studies reported in the New England Journal of Medicine…
Portola's andexanet alfa and Boehringer Ingelheim's idarucizumab are both due to be filed for approval this year, with big…